Lead Product(s): IC 265
Therapeutic Area: Ophthalmology Product Name: IC 265
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Ophthalmology Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 28, 2020
The exclusive license is for ophthalmic indications in China and other countries of Southeast Asia. The agreement will accelerate the development of IC 265 and IC 270 in both China and the U.S.